Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tech trial aims to get heart failure patients moving

NCT ID NCT07171372

Symptom relief Sponsor: Abant Izzet Baysal University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a personalized system that uses a mobile app and smart wristband to encourage physical activity in 82 adults with heart failure. Participants get custom activity goals, real-time feedback, and motivational support over 12 months. The goal is to see if this approach can improve exercise adherence and reduce sedentary behavior.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IoT-based physical activity monitoring system (mobile app and smart wristband)
What this could lead to
If successful, this system could help heart failure patients become more active and improve their daily functioning and quality of life.
What could go wrong
This is a small, early-stage trial with 82 participants, so results may not apply to all heart failure patients. The intervention relies on technology and motivation, which may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 82 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of HF confirmed by echocardiographic examination, * Heart failure characterized by reduced ejection fraction (HFrEF), * Individuals aged 18-75 years, * New York Heart Association (NYHA) functional class I, II, or III, * No evidence of ischemia on coronary angiography performed within the last three months, * No physical limitations preventing exercise, * Standardized Mini-Mental State Examination (MMSE) score ≥ 25, * Ownership of a smartphone compatible with the mobile application to be used in the study. Exclusion Criteria: * Presence of an ischemic lesion requiring revascularization on coronary angiography, * History of major cardiac surgery within the last three months, * Worsening dyspnea at rest and exercise intolerance, * Presence of arrhythmia problems such as ventricular tachyarrhythmia or atrial fibrillation, * Uncontrolled diabetes (Hemoglobin A1C ≥ 7 mg/dl), * Presence of chronic pulmonary disease or renal insufficiency, * Symptomatic postural hypotension (≥20 mmHg systolic drop), * Score ≥ 9 on the Edmonton Frail Scale (moderate to severe frailty), * Morbid obesity (BMI \> 40 kg/m²), * Neuropsychiatric disorders severely impairing cognitive functions such as dementia or Alzheimer's disease, * Unwillingness to participate in the exercise program.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure Motor Activity Sedentary Behavior systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Reduced ejection fraction heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.